You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖-B(02696.HK):HLX10聯合HLX04治療晚期肝細胞癌(HCC)的2期臨牀研究完成首例患者給藥
格隆匯 09-25 18:43

格隆匯9月25日丨復宏漢霖-B(02696.HK)然宣佈,近日,公司重組抗PD-1人源化單克隆抗體注射液(HLX10)聯合重組抗VEGF人源化單克隆抗體注射液(HLX04)治療晚期肝細胞癌(HCC)的2期臨牀研究已完成首例患者給藥。

該項研究是在經標準治療後發生疾病進展或不可耐受毒性反應的晚期肝細胞癌患者中開展的一項單臂、開放、多中心的臨牀2期研究,旨在評估HLX10聯合HLX04在治療晚期肝細胞癌中的臨牀療效、安全性和耐受性。

HLX10是公司自主研發的創新型單克隆抗體項目,已相繼獲得美國、中國台灣地區及中國大陸的臨牀試驗批准,可用於多種實體瘤的治療,單藥現已進入2期臨牀試驗階段,正進一步探索其用於治療慢性乙型肝炎的可能性。HLX10還可聯合其他產品開展免疫聯合療法,廣泛用於實體瘤治療。

HLX04是貝伐珠單抗生物類似藥,為重組抗VEGF人源化單克隆抗體注射液,是本公司自主研發的單克隆抗體生物類似藥,主要用於結直腸癌、非小細胞肺癌及濕性年齡相關性黃斑變性和糖尿病性視網膜病變等眼部疾病的治療。現就轉移性結直腸癌適應症於中國開展3期臨牀試驗

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account